Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-BOOST-LC
NCT07426055Phase 3Recruiting
- Sponsor
- Affidea
- Start
- Mar 2026
- Primary completion
- Dec 2033
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) (4 arms), sponsored by Affidea. Primary endpoints: Failure-Free Survival up to 10 years and Metastasis-Free Survival up to 10 years. Started Mar 2026; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07426055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07426055.